PIK3CA and endometrial cancer: As we suggest in this paper, a PIK3CA or PTEN status may provide additional therapeutic implications in advanced or metastatic endometrial cancer, considering the relatively high frequency of PIK3CA mutation or PTEN loss, regardless of four molecular groups [33].